FDAsafety guidance72% confidence
FDA Drug Competition Action Plan | Maximizing scientific and regulatory clarity with respect to complex generic drugs
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to regulatory agencies.
Regulatory Analysis
Complex generic products are typically harder to develop, which means that many complex products face less competition than other products, and therefore can be more expensive and less accessible to the patients who need them.
Supporting Context
- Therapeutic area
- Hepatology · Herbal Medicine
- Sub-indication
- General
Related signal: Concerns Raised Over Hepatotoxicity of Epimedium brevicornu Maxim.